Delving into the Latest Updates on Avir Pharma, Inc. with Synapse

概览

疾病领域	数量

感染	3
神经系统疾病	2
免疫系统疾病	2
血液及淋巴系统疾病	2
内分泌与代谢疾病	1
肿瘤	1

排名前五的药物类型	数量

小分子化药	6
合成多肽	1
重组多肽	1

排名前五的靶点	数量

prothrombin(凝血酶原)	1
PBPs(细菌青霉素结合蛋白家族)	1
SRC x Tubulin	1
PP2A(蛋白质磷酸酶2A)	1
fungal CYP51A1(真菌细胞色素P450家族成员51)	1

关联

9

项与 Avir Pharma, Inc. 相关的药物

Tirbanibulin

特班布林

靶点

SRC x Tubulin

作用机制

SRC抑制剂 [+1]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2020-12-14

Ceftobiprole Medocaril Sodium

头孢比罗酯钠

靶点

PBPs

作用机制

PBPs抑制剂

在研机构

Basilea Pharmaceuticals Deutschland GmbH [+3]

原研机构

Basilea Pharmaceutica AG

在研适应症

社区获得性细菌性肺炎 [+6]

非在研适应症

发热 [+10]

最高研发阶段批准上市

首次获批国家/地区

加拿大

首次获批日期2018-03-20

Isavuconazonium Sulfate

硫酸艾沙康唑鎓

靶点

fungal CYP51A1

作用机制

fungal CYP51A1抑制剂

在研机构

Basilea Pharmaceuticals Deutschland GmbH [+9]

原研机构

Basilea Pharmaceutica AG

在研适应症

隐球菌病 [+4]

非在研适应症

急性髓性白血病 [+7]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2015-03-06

100 项与 Avir Pharma, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Avir Pharma, Inc. 相关的专利（医药）

登录后查看更多信息

4

项与 Avir Pharma, Inc. 相关的文献（医药）

2022-11-15·Blood

Epidemiology and Disease Burden of Mucormycosis in Canada: Canmus Registry

作者: Mah, Allison ; Husain, Shahid ; Luong, Me-Linh ; Cheng, Matthew P ; Dufresne, Phillipe ; Haider, Shariq ; Schwartz, Ilan ; Robinson, Stephen ; Bow, Eric ; Rotstein, Coleman ; Bai, Tony D ; Vinh, Donald ; Faulkner, Jodi ; Buchan, C.Arianne ; Dufresne, Simon Frédéric ; Shalhoub, Sarah ; Sanche, Stephen ; Vanniyasingam, Thuva

2022-07-04·Expert Review of Pharmacoeconomics & Outcomes Research4区 · 医学

Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada

4区 · 医学

Article

作者: Guinan, K. ; Rotstein, C. ; Dufresne, S. Frédéric ; Claveau, D. ; Beauchemin, C.

BACKGROUNDInvasive mold infections (IMI) directly impact life expectancy, especially with delayed therapy. Among IMI, aspergillosis (IA) is more common than mucormycosis (IM), resulting in IA-targeted empirical treatment with voriconazole for suspected invasive pulmonary aspergillosis (IPA), despite IM ineffectiveness. Recently, isavuconazole was approved in Canada for IA and IM. The primary objective was to assess the cost-effectiveness of isavuconazole compared to voriconazole for suspected IPA in Canada. A secondary objective was to assess the impact of varying time horizons to address the wide spectrum of life expectancies, according to patients underlying diseases.RESEARCH DESIGN AND METHODSA 5-year decision-tree was developed from the Canadian Ministry of Health (MoH) and societal perspectives. Efficacy parameters were extracted from SECURE/VITAL trials. Costs included treatment acquisition, hospitalization, adverse events and productivity loss. 3- and 10-year time horizon alternative scenarios and extensive sensitivity analyses were also conducted.RESULTSFrom a MoH perspective, isavuconazole compared to voriconazole resulted in an incremental cost-utility ratio (ICUR) of $C30,160/QALY. 3- and10-year ICURs were also cost-effective, relative to a willingness-to-pay threshold of $C50,000/QALY.CONCLUSIONSThis study demonstrates that, in comparison to voriconazole, isavuconazole is a cost-effective strategy for the treatment of patients with suspected IPA, regardless of their life expectancy.

2021-12-01·Advances in Therapy3区 · 医学

Economic Evaluation of Budesonide Orodispersible Tablets for the Treatment of Eosinophilic Esophagitis: A Cost–Utility Analysis

3区 · 医学

Article

作者: Dellon, E S ; Chan, E S ; Castonguay, A ; Feagan, B G ; Beauchemin, C ; Ma, C ; Cook, J ; Claveau, D ; Waserman, S

INTRODUCTIONBudesonide orodispersible tablets (BOT) have been approved in Europe and Canada for the treatment of eosinophilic esophagitis (EoE), a rare and chronic disease. The objective of this study was to assess the economic impact of BOT on both the induction and maintenance of clinico-pathological remission of EoE by performing a cost-utility analysis (CUA).METHODSFor both the induction and maintenance settings, BOT was compared to no treatment in a target population of adult patients with EoE non-responsive to proton pump inhibitor (PPI) treatment. Markov models were developed for the induction and maintenance settings over 52-week and life-time horizons, respectively. Analyses were performed from both a Canadian Ministry of Health (MoH) and societal perspective. The resulting incremental cost-utility ratios (ICURs) were compared to a willingness-to-pay (WTP) threshold of $50,000 Canadian dollars/quality-adjusted life-year (QALY). Sensitivity and scenario analyses were conducted to assess the robustness of the base-case results.RESULTSIn the base-case probabilistic analysis, BOT compared to no treatment resulted in an ICUR of $1073/QALY and $30,555/QALY from a MoH perspective in the induction and maintenance settings, respectively. BOT was a cost-effective option for both induction and maintenance in > 99% of Monte Carlo simulations. In the scenario analyses, the deterministic ICUR of BOT compared to no treatment varied from $682/QALY to $8510/QALY in the induction setting and $21,005/QALY to $55,157/QALY in the maintenance setting.CONCLUSIONBOT was cost-effective compared to no treatment for both the induction and maintenance of clinico-pathological remission of EoE in patients non-responsive to PPIs.

100 项与 Avir Pharma, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Avir Pharma, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

8

1

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

美沙拉嗪 ( PP2A )	溃疡性直肠炎更多	批准上市
头孢比罗酯钠 ( PBPs )	医院获得性肺炎更多	批准上市
布地奈德 ( GR )	嗜酸粒细胞性食管炎更多	批准上市
特立帕肽 ( PTH1R )	骨质疏松症更多	批准上市
比伐芦定 ( prothrombin )	冠心病更多	批准上市